What stage does Polaris Partners invest at?

Polaris Partners invests at the Seed, Series A, Series B, Series C, Growth stages.

What is Polaris Partners's typical check size?

Polaris Partners typically writes checks of $500K – $5M.

What sectors does Polaris Partners focus on?

Polaris Partners focuses on Biotech, Consumer, Digital Health, Healthtech.

Where is Polaris Partners located?

Polaris Partners is headquartered in Boston, US.

Polaris Partners

Venture capitalActively deployingoperating company · company profile

Boston · Seed–Growth · 36 people tracked

Also known as Polaris Growth Fund · POLARIS GROWTH MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Polaris Partners emphasizes real partnership as the foundation for building great companies. For nearly three decades, the firm has collaborated with talented biotech and healthcare entrepreneurs, backing transformational companies in these fields. Its approach centers on doing well by working together with founders throughout the company-building journey.

Invests inBiotech Consumer Digital Health Healthtech Asia-Pacific Boston Europe United States

Source: firm website, verified Aug 25, 2026.

Stage

Seed–Growth

Check

$500K – $5M

Boston, Massachusetts, US

Instruments

Equity

Founded

1995

Last 12 months

10 investments

AUM

$4.2B

Tracked investments

Team · 36 people

from the firm's website & public directories

Jon Flint· Founding Partner· Massachusettsin 𝕏

Jon Flint co-founded Polaris Partners with Steve Arnold and Terry McGuire in 1996. He began his venture career in 1984 at Burr, Egan, Deleage & Co., where he became a General Partner and helped build the firm's technology portfolio, having previously worked as a litigation associate at the Boston law firm Testa, Hurwitz and Thibeault and served on research teams for the Nixon Impeachment Inquiry Staff and the Watergate Special Prosecution Force. In 2005 he conceived of and co-founded Living Proof, and in 2015 he and Terry McGuire formed Polaris Founders Capital to invest their own capital across stages and sectors.

j•••@polarispartners.comreveal

Terry McGuire· Founding Partner· Massachusettsin

t•••@polarispartners.comreveal

Alan Crane· Entrepreneur Partner

Alan Crane joined Polaris Partners in 2002 as an entrepreneur partner, focusing on building and investing in healthcare companies. He has held founder, CEO, and Chairman roles across ten Polaris companies, including co-founding Zag Bio, Seismic Therapeutic, and Dyno Therapeutics, and founding Pandion Therapeutics (acquired by Merck). He was previously president and CEO of Momenta Pharmaceuticals (acquired by J&J) and SVP of corporate development at Millennium Pharmaceuticals, and holds degrees from Harvard College, Harvard Graduate School of Arts & Sciences, and Harvard Business School.

a•••@polarispartners.comreveal

Alexandra Cantley· Managing Partner· New York, New Yorkin 𝕏

Alexandra Cantley is a managing partner at Polaris Partners, which she joined in 2019, working from the New York office with a focus on early-stage biotech and healthcare investments. Before Polaris, she was part of the initial research team at Inzen Therapeutics and previously held a research fellowship at Vertex Pharmaceuticals. She holds a PhD in Chemical Biology from Harvard University and completed her undergraduate studies at New York University.

Amir Nashat· Entrepreneur Partner· Bostonin 𝕏

Amir Nashat is an entrepreneur partner at Polaris Partners in Boston, where he invests in healthcare companies and takes on executive roles inside portfolio companies. He joined the firm in 2002 and serves as a managing partner of Polaris Funds VI through IX. He has repeatedly stepped in as CEO of Polaris-backed startups, including Dewpoint Therapeutics, Jnana, Living Proof, Olivo Labs, Paratus Sciences, and Sun Catalytix, and is currently CEO of Souffle Therapeutics. He earned a doctorate in chemical engineering at MIT under Robert Langer and holds materials science and mechanical engineering degrees from UC Berkeley, and was named to the Forbes Midas List in 2016.

a•••@polarispartners.comreveal

Amy Schulman· Managing Partner· Mount Pleasant, South Carolinain

Amy Schulman is a managing partner at Polaris Partners focused on healthcare companies and early stage biotech startups. She joined the firm in 2014 and co-founded the Polaris Innovation Fund in 2017, which she continues to manage. Before Polaris she held roles at Pfizer including general counsel and president of Pfizer Nutrition and Pfizer Consumer Healthcare, was a partner at DLA Piper, and began her career at Cleary Gottlieb Steen & Hamilton; she is also a Senior Lecturer at Harvard Business School and holds degrees from Wesleyan University and Yale Law School.

a•••@polarispartners.comreveal

Brian Chee· Managing Partner· San Francisco, Californiain 𝕏

Brian Chee is a managing partner at Polaris Partners in San Francisco who invests in healthcare companies. He joined Polaris as an associate in Boston shortly after the firm's founding in 1996, and previously worked at Goldman Sachs in New York and San Francisco and at Baxter Healthcare, where he developed experience across medical devices, pharmaceuticals, and biotechnology. He holds a BS from the United States Military Academy at West Point and an MBA from the Tuck School of Business at Dartmouth College, and served as a Captain in the US Army Corps of Engineers.

b•••@polarispartners.comreveal

Chen-Ee Lee· Partner

Ellie McGuire· Managing Partner· Boston, Massachusettsin

Ellie McGuire is a managing partner in Polaris Partners' Boston office and manages the Polaris Innovation Fund, which she co-founded. Before Polaris, she was head of business development at Lyndra and held leadership and consulting roles in business development, operations, and strategy at life science companies including Arsia Therapeutics, SQZ Biotechnologies, and XTuit Pharmaceuticals. She also serves as an expert in residence for the Harvard Office of Technology Development.

e•••@polarispartners.comreveal

Gary Swart· Operating Partner· Athertonin 𝕏

Gary Swart is an operating partner at Polaris Partners in San Francisco, where he invests in healthcare services and products. He previously served as CEO of oDesk (later Upwork), which merged with Elance, and earlier held roles as Chief Revenue Officer of Intellibank and a business unit executive at IBM following its acquisition of Rational Software. He also mentors at accelerators including Alchemist and StartX.

g•••@polarispartners.comreveal

Jonathan Ang· Entrepreneur Partner· Singapore

Jonathan Ang joined Polaris Partners in 2023 as an entrepreneur partner in the firm's Singapore office, where he focuses on investing in, building, and scaling healthcare companies. Previously he was a Director on the Life Sciences Team at Temasek International in Singapore, managing its global healthcare services investment strategy and co-leading investments across multiple regions. He began his career on Cowen's Health Care Banking Team in New York and London, and holds an honors degree in Economics from The Wharton School of the University of Pennsylvania.

Darren Carroll· Partner· Boston, Massachusettsin

Sabrina Chiasson· Partner· Boston, Massachusettsin

Brian Lewis· Director, Legal & Investment Analytics· San Franciscoin

Brian Lewis joined Polaris in 2019 as director of legal and investment analytics in the firm's San Francisco office, where he handles investment analytics projects along with legal operations and deal matters. He previously worked at Latham & Watkins LLP, first as a senior paralegal and then as a quantitative analysis manager in the corporate department, supporting financial and capitalization modeling for equity financings, acquisitions, and IPOs. He holds a BS in Mathematics from UCLA, a paralegal certification from San Francisco State University, and an MBA from UC Berkeley's Haas School of Business.

Joanna Zesiger· Director of Finance

Leah Paquette· Director of Operations and LP Relations· Boston, Massachusetts, United Statesin

Nil Gural· Principal· New York

Nil Gural is a principal at Polaris Partners, which she joined in 2022, where she works on biotech and healthcare investments. She previously was a manager in Bain & Company's healthcare practice covering pharma and medical devices, and earlier was part of the founding team at Glympse Bio, contributing to its platform technology. She holds a PhD from the Harvard-MIT HST program, where she was an HHMI fellow, and a BS in Biomedical Engineering from Washington University in St. Louis.

Paulina Hill· Principal𝕏

Annie Wihongi· Executive Assistant and Office Manager

Daniel Anderson· Scientific Advisory Committee Member

Dave Barrett· Senior Advisory Partner· Boston, Massachusettsin 𝕏

Dave Barrett is a senior advisory partner in Polaris Partners' Boston office who focuses on healthcare technology. He joined Polaris in 2000 after an operating career that included serving as COO of Calico, SVP of worldwide operations at Pure Atria/Rational Software, and various leadership roles over 12 years at Lotus Development. He also serves as a managing partner of Polaris Funds VI-IX and the Polaris Healthcare Technology Opportunities Fund, with particular interest in AI and ML platforms for care management.

d•••@polarispartners.comreveal

Elizabeth Dowd· Executive Assistant and Office Manager· Boston

Elizabeth Dowd joined Polaris in 2018 as an executive assistant and office manager in the firm's Boston office. Before Polaris, she provided administrative support to various non-profits and worked as a tour guide at historic sites.

Harold Friedman· Chief Financial Officer· San Francisco, California, United Statesin

Harold Friedman serves as Chief Financial Officer at Polaris Partners. He has experience managing financial operations for venture capital and private equity firms with assets ranging from $200 million to $4.5 billion, and works with managing directors, limited partners, and external service providers.

h•••@polarispartners.comreveal

JoAnne Trayers· Executive Assistant· Waltham, Massachusetts, United Statesin

JoAnne Trayers joined Polaris Partners in 2001 as executive assistant to co-founder Jon Flint on the technology side of the firm, and more recently moved to the healthcare team supporting Alan Crane. Before Polaris, she supported the CEO and CFO at Allaire Corporation, worked with the senior management team at Powersoft Corporation, and served as operations manager at FirstSense Software.

Kara Greenwood· Executive Assistant· New York

Kara Greenwood joined Polaris in 2023 as an executive assistant supporting the firm's New York office. She has worked as a c-suite executive assistant across various industries, with prior roles supporting executives at Goldman Sachs, SBE Entertainment, a private family office, and Virtue Labs. She holds a BS in Communications from The University of Tennessee Knoxville.

Kirti Anand· Fund Controller

Kirti Anand joined Polaris in 2022 as fund controller, where she handles fund management and reporting. She previously worked as an Audit Senior Manager at BDO in the asset management group, focusing on alternative investments across venture capital and private equity clients. She is a Certified Public Accountant (Inactive) and holds a Master of Accounting degree from Golden Gate University.

Lauren Crockett· General Counsel and Chief Compliance Officer· San Franciscoin

Lauren Crockett is general counsel and chief compliance officer at Polaris Partners, which she joined in 2019, handling legal, compliance, and operational matters including fundraising, fund management, and deal structuring. She previously served as assistant general counsel at LendingClub Corporation and was a corporate associate at Latham & Watkins, and earlier held legal and government affairs roles at Bain Capital. She holds a JD from Harvard Law School and a BA in history from Dartmouth College.

Liz Wong· Executive Assistant and Office Manager· San Francisco

Liz Wong joined Polaris Partners in 2025 as executive assistant and office manager for the firm's San Francisco office. She previously provided administrative and office management support to finance, advertising, and tech companies including FCB Global, Vantage Point Capital, and Intuit.

Manik Kuchroo· Senior Associate

Maureen St. Pierre· Portfolio Analyst· Boston, Massachusettsin

Maureen St. Pierre joined Polaris Partners in 2002 as a portfolio analyst supporting the finance and investor relations teams. Before Polaris, she worked in auditing, budget and cost accounting, and investment pension financial management at John Hancock Financial Services. She holds a BS in Finance from Siena College and an MBA from Babson College.

Megan Jahan· Accounting Manager· San Francisco

Megan Jahan is the accounting manager at Polaris Partners, which she joined in 2018 in the San Francisco office, working with the finance team on management company accounting. She previously spent over fourteen years in various accounting positions at VantagePoint Capital Partners. She holds a degree in Administrative Office Management from Renton College.

Michelle Pizzi· Senior Operations Associate· Boston

Michelle Pizzi joined Polaris Partners' Boston office in 2019 as a senior operations associate, where she supports the operations team's initiatives. She previously spent five years at The Fulham Group, managing the office and working with the finance department, and earlier held support roles at Mercer. She holds a BA in marketing with a minor in finance from Assumption College.

Molly Wilson· Executive Assistant· Boston, Massachusetts, United Statesin

Molly Wilson joined Polaris in 2002 as executive assistant to co-founder and general partner Terry McGuire. Since 2010, she has co-founded and served as executive administrator for the Global Venture Capital Congress, organizing its annual meetings of venture capital associations worldwide. Her earlier career included executive assistant roles supporting leadership at EMC Corporation, Arch Wireless, Oak Industries, and Brandeis University, and she is a graduate of The Katharine Gibbs School in Boston.

Robert Langer· Scientific Advisory Committee Member

Sean Thornton· Office Coordinator· Boston

Sean Thornton joined Polaris Partners' Boston office in 2022 as an office coordinator. Before Polaris, he worked as an assistant office manager at the Above the Rim sports complex.

Pat Mulach· Vice President· Boston, Massachusettsin 𝕏

Founder mafia

4 people who came through Polaris Partners went on to found or lead other companies.

Amir NashatEntrepreneur PartnerFounded Paratus Sciences +1 Robert LangerScientific Advisory Committee MemberFounded Lyndra +1 Alan CraneEntrepreneur PartnerFounded Dyno Therapeutics Amy SchulmanManaging PartnerFounded Lyndra

What they invest in

from 63 of 78 portfolio companies

Biotech ×44Healthtech ×22AI & Machine Learning ×16Medical Devices ×15Enterprise Software ×9Digital Health ×7Deep Tech ×6SaaS ×5

HQs:United States×69Netherlands×1

Investments · 78 tracked

founders shown can be your intro path

By year:2026 · 5 2025 · 6 2024 · 5 2023 · 3 2022 · 10 2021 · 4 2020 · 4 2019 · 1 2018 · 3 2017 · 5 2016 · 8 2015 · 1168 dated

Adagio TherapeuticsNASDAQ: IVVDNov 2022SEC filingmedium confidence

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)Halley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)Ellie Hershberger(Executive Officer)

Board seatTerry McGuireTerrance G. McGuire· per SEC Form D · $23.7M raise · filed Nov 2022

Co-investorsMithril Capital Management Veltro Argento

Alectoralector.com in 𝕏NASDAQ: ALECSep 2015SEC filingmedium confidence

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in

BoardCarl Gordon(Director)

Board seatTerry McGuire· per SEC Form D · $32.3M raise · filed Sep 2015

Co-investorsForesite Capital Mission Bay Capital Mission Biocapital MRL Ventures Fund SV Health Investors

aTYR PHARMAatyrpharma.comNASDAQ: ATYRMar 2015SEC filingmedium confidence

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Frederic Chereau(Executive Officer)

BoardAkkaraju Srinivas(Non-Management Director)

Board seatAmir Nashat· per SEC Form D · $76.3M raise · filed Apr 2015

Co-investorsCardinal Partners EcoR1 Capital Sofinnova Ventures Domain Partners Samsara BioCapital

Camp4 Therapeutics CorpNASDAQ: CAMPJun 2022SEC filingmedium confidence

BiotechCambridge, US

JOSH MANDEL-BREHM(Executive Officer, Director)RICHARD YOUNG(Director)

BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)in

Board seatAmir Nashat· per SEC Form D · filed Jun 2022

Co-investors5AM Ventures Andreessen Horowitz Longwood Fund

Cardlyticscardlytics.com in 𝕏NASDAQ: CDLXMay 2017SEC filingmedium confidence

Cardlytics operates a commerce media platform that uses card-linked purchase data to deliver targeted offers and closed-loop measurement for marketers and advertisers, and personalized rewards programs for banks and publishers.

AdTechFintechMarketing TechAtlanta, US

Scott Grimes(Executive Officer, Director)inLynne Laube(Executive Officer, Director)Kirk Somers(Executive Officer)David Evans(Executive Officer)

BoardJohn Klinck(Director)inMark Johnson(Director)in

Board seatBryce Youngren· per SEC Form D · $11.9M raise · filed Jun 2017

Co-investorsBaroda Ventures Canaan Partners Kinetic Ventures, L.L.C.Next Coast Ventures Savano Capital Partners Hyperplane Venture Capital +1 more

Cartesian Therapeutics (NASDAQ: RNAC)cartesiantherapeutics.com in 𝕏NASDAQ: RNACDec 2016SEC filingmedium confidence

Cartesian Therapeutics is a biotechnology company developing cell therapies, formed through the November 2023 merger with Selecta.

BiotechHealthtechWatertown, US

Metin Kurtoglu(Executive Officer)Chris Jewell(Executive Officer)Carsten Brunn(President, CEO & Chairman of the Board)inEmily English(Executive Officer)Blaine Davis(Executive Officer)Stephen Smolinksi(Executive Officer)

Board seatAmir Nashat· per SEC Form D · $70M raise · filed Jan 2020

Co-investorsK2 HealthVentures Maryland TEDCO Schooner Capital TEDCO

Cyclerion Therapeuticscyclerion.comNASDAQ: CYCNApr 2019SEC filinghigh confidence

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.

BiotechDigital HealthMental HealthCambridge, US

William Huyett(Executive Officer)Mark G. Currie(Executive Officer)Ole Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)George Conrades(Director)

Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $24.3M raise · filed Aug 2020

Co-investorsPappas Capital

Dare Biosciencedarebioscience.comNASDAQ: DAREOct 2016SEC filingmedium confidence

Daré Bioscience is a women's health biotech company that conducts end-to-end clinical development of targeted therapeutics and products for conditions across areas such as contraception, menopause, vaginal infections, and sexual wellness.

BiotechDigital HealthFemTechSan Diego, US

MarDee Haring-Layton(Chief Accounting Officer)Sabrina Martucci Johnson(Founder & Chief Executive Officer)Christopher D.T. Guiffre(Executive Officer, Director)Gregg Beloff(Executive Officer)Alejandra V. Carvajal(Executive Officer)Adrian Senderowicz(Executive Officer)

Board seatAlan Crane· per SEC Form D · $1 raise · filed Oct 2016

Fate Therapeuticsfatetherapeutics.comNASDAQ: FATEMay 2015SEC filingmedium confidence

Fate Therapeutics develops clinical-stage cell therapy drug candidates for autoimmune diseases and cancer, using an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products.

BiotechHealthtechSan Diego, US

Christian Weyer(Executive Officer, Director)J. Scott Wolchko(Executive Officer)Daniel Shoemaker(Executive Officer)

BoardJohn Mendlein(Director)William Rastetter(Director)

Board seatAmir Nashat· per SEC Form D · $10.3M raise · filed Aug 2016

Co-investorsSanofi Ventures Venrock

Fractylfractyl.com in 𝕏NASDAQ: GUTSJan 2022SEC filingmedium confidence

Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.

BiotechHealthtechMedical DevicesLexington, US

HARITH RAJAGOPALAN(Executive Officer, Director)JAY CAPLAN(Executive Officer, Director)Harith Rajagopalan(Executive Officer, Director)inLISA DAVIDSON(Executive Officer)Ajay Royan(Director)Christopher Gabrieli(Director)

Board seatAmy Schulman· per SEC Form D · $20.1M raise · filed Jan 2022

Co-investorsBessemer Venture Partners Catalio Capital Management, LP Emergent Medical Partners, LLP Mithril Capital Management Veltro Argento

Pulmatrixpulmatrix.comNASDAQ: PULMDec 2018SEC filingmedium confidence

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.

BiotechDeep TechHealthtechMedical DevicesFramingham, US

Anand Varadan(Director)Richard Batycky(Director)Peter Ludlum(Interim CEO; Interim CFO)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)

BoardRichard Conley(Director)

Board seatTerrance McGuire· per SEC Form D · $3.7M raise · filed Dec 2018

Co-investors5AM Ventures ARCH Venture Partners

Scholar Rockscholarrock.com in 𝕏NASDAQ: SRRKDec 2015SEC filingmedium confidence

Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)

BoardKristina Burow(Director)inKatrine Bosley(Director)Michael Gilman(Director)

Board seatAmir Nashat· per SEC Form D · $40M raise · filed Jan 2016

Co-investorsAisling Capital ARCH Venture Partners EcoR1 Capital

Scholar Rock Holding Corp, Inc.NASDAQ: SRRKDec 2017SEC filingmedium confidence

Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Alan Buckler(Executive Officer)

Board seatAmir Nashat· per SEC Form D · $47M raise · filed Jan 2018

Co-investorsSamsara BioCapital ARCH Venture Partners

Seer BiosciencesNASDAQ: SEERDec 2017SEC filingmedium confidence

BiotechBoston, US

Omid Farokhzad(Director)Philip Ma(Executive Officer)Shadi Aryanpour(Executive Officer)David Singer(Director)

BoardRobert Langer(Director)

Board seatTerrance McGuire· per SEC Form D · $6M raise · filed Jan 2018

Tectonic TherapeuticNASDAQ: TECXApr 2021SEC filingmedium confidence

BiotechWatertown, US

Timothy Springer(Director)Andrew Kruse(Director)Timothy A. Springer(Director)Alise Reicin(Executive Officer, Director)Daniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)

Board seatTerry McGuire· per SEC Form D · $80.1M raise · filed Apr 2021

Co-investorsAlly Bridge Group Clarus EcoR1 Capital Soleus Capital Vida Ventures

Vaccinexvaccinex.comOTC: VCNXMay 2017SEC filingmedium confidence

Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer.

BiotechHealthtechMedical DevicesRochester, US

Maurice Zauderer, Ph.D.(Director, Executive Officer)Maurice Zauderer(Executive Officer, Director)Elizabeth Evans(Executive Officer)Ernest S. Smith Ph.D.(Executive Officer)Jill Sanchez(Executive Officer)Ernest S. Smith(Executive Officer)

Board seatAlan Crane· per SEC Form D · $18.2M raise · filed Jul 2017

X4 PharmaceuticalsNASDAQ: XFORApr 2016SEC filinghigh confidence

BiotechBoston, US

Mary DiBiase(Executive Officer)Christophe Arbet-Engels(Executive Officer)David Kirske(Executive Officer)John Volpone(Executive Officer)Mark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)

Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $50.5M raise · filed May 2017

Co-investorsOmega Funds

Leyden Labsleydenlabs.com in✓ verified

Leyden Labs develops nasal sprays that provide immediate protection against entire families of respiratory viruses through passive immunity, without relying on the body's own immune response.

BiotechHealthtechImpact & Social GoodMedical DevicesLeiden, NL

Koenraad Wiedhaup(Founder & CEO)inRonald Brus(Founder and Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)in

Co-investorsClavystBio Invest-NL Qiming Venture Partners Connecticut Innovations F-Prime Capital GV (Google Ventures)+1 more

1366 TechnologiesApr 2016SEC filingmedium confidence

Bedford, US

Franciscus J.A. van Mierlo(Executive Officer, Director)

BoardReidar Langmo(Director)Robert Metcalfe(Director)Carmichael Roberts(Director)Yasheng Huang(Director)Bruce Sohn(Director)

Board seatAmir Nashat· per SEC Form D · $30M raise · filed May 2016

480 BiomedicalNov 2016SEC filingmedium confidence

Watertown, US

Maria Palasis(Director, Executive Officer)

BoardRobert Langer(Director)Guido Neels(Director)Richard Mott(Director)Carmichael S. Roberts(Director)

Board seatTerrance McGuire· per SEC Form D · $6M raise · filed Nov 2016

Agbiomeagbiome.comFeb 2022AcquiredSEC filingmedium confidence

US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.

AgTechResearch Triangle Park, US

Scott Uknes(Manager)Eric Ward(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)

BoardThomas Dietz(Manager)Kristina Burow(Manager)in

Board seatAmir Nashat· per SEC Form D · $117.2M raise · filed Feb 2022

Co-investorsAliment Capital Blue Horizon Corporation Pontifax AgTech ARCH Venture Partners Novalis LifeSciences

Amagma, Inc.Dec 2022SEC filingmedium confidence

HealthtechWaltham, US

Tillman Gerngross(Executive Officer, Director)

Board seatAmy Schulman· per SEC Form D · $10M raise · filed Dec 2022

Co-investorsAtlas Venture

Ankyra Therapeuticsankyratx.com in 𝕏May 2020SEC filingmedium confidence

Ankyra Therapeutics is a biopharmaceutical company developing drugs, with a team that has collectively contributed to bringing seven drugs to global market approval.

BiotechDeep TechHealthtechMedical DevicesAustin, US

Tillman Gerngross(Executive Officer, Director)

Board seatTerrance McGuire· per SEC Form D · $14.5M raise · filed May 2020

Co-investorsGV (Google Ventures)Mithril Capital Management

Athletes' PerformanceFeb 2016SEC filingmedium confidence

Phoenix, US

Mark Verstegen(Executive Officer, Director)Dan Burns(Executive Officer, Director)Peter Hotz(Director)Timothy Kilgallon(Director)Rick Smith(Executive Officer)Jonathan Flint(Director)in

Board seatJonathan Flint· per SEC Form D · $193.8K raise · filed Feb 2016

Co-investorsABS Capital Partners

Auron Therapeuticsaurontherapeutics.comDec 2025SEC filingmedium confidence

BiotechNewton, US

Katharine Yen(Executive Officer, Director)Kate Yen(Founder)inChristopher Guiffre(Executive Officer)

BoardAlon Lazarus(Director)Anna French(Director)

Board seatAlexandra Cantley· per SEC Form D · $42.3M raise · filed Dec 2025

Co-investorsDCVC (Data Collective)

Be Me HealthNov 2022SEC filingmedium confidence

Marblehead, US

Scott Cousino(Director)Ronald Geraty(Executive Officer, Director)

Board seatAlexandra Cantley· per SEC Form D · $8.2M raise · filed Nov 2022

Blue Rabbit VenturesMar 2021SEC filingmedium confidence

BiotechPortland, US

Benjamin J. Shaw(Executive Officer, Director)

BoardEdward L. Cahill(Director)

Board seatTerrance G. McGuire· per SEC Form D · $14.5M raise · filed Apr 2021

ByHeartbyheart.comMay 2026SEC filingmedium confidence

ByHeart is an infant formula company navigating an FDA return-to-market process following a product outbreak investigation.

ConsumerDirect to ConsumerFoodTechHealthtechNew York, US

Mia B. Funt(Executive Officer, Director)Ron Belldegrun(Executive Officer, Director, Promoter)Georg Krause-Vilmar(Executive Officer)Niall Mullane(Executive Officer)

BoardHemi Zucker(Director)in

Board seatAmy Schulman· per SEC Form D · $95.5M raise · filed May 2026

Co-investorsEvolution VC Partners OCV Partners Red Sea Ventures Vida Ventures

Cardurion Pharmaceuticals, Inc.Dec 2022SEC filingmedium confidence

BiotechBurlington, US

Michael Mendelsohn(Executive Officer, Director)

BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)inNicholas Downing(Director)

Board seatAmy Schulman· per SEC Form D · $17.5M raise · filed Dec 2022

Co-investorsBain Capital Life Sciences Bain Capital NEA Secondary Third Rock Ventures

Cirrus Therapeutics, Inc.Aug 2025SEC filingmedium confidence

Cambridge, US

Ying Kai Chan(Executive Officer, Director, Promoter)Andrew Dick(Director, Promoter)

BoardKhoo Shih(Director)

Board seatAlexandra Cantley· per SEC Form D · $15.7M raise · filed Aug 2025

Crossbow Therapeuticscrossbowtx.com inSep 2025SEC filingmedium confidence

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in

BoardSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in

Board seatAlexandra Cantley· per SEC Form D · $80M raise · filed Sep 2025

Co-investorsMPM BioImpact Pfizer Venture Investments Pfizer Ventures Taiho Ventures, LLC

Dewpoint Therapeuticsdewpointx.com inFeb 2022SEC filingmedium confidence

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)Ameet Nathwani, M.D.(Executive Officer, Director)

Board seatAmir Nashat· per SEC Form D · $150M raise · filed Feb 2022

Co-investorsARCH Venture Partners EcoR1 Capital Samsara BioCapital 6 Dimensions Capital General Catalyst Innovation Endeavors +5 more

Drizlydrizly.comApr 2015SEC filingmedium confidence

On-demand alcohol delivery platform providing consumers with a better way to shop for wine and spirits

Sherborn, US

Justin Robinson(Executive Officer)inNicholas Rellas(Executive Officer, Director)James Cory Rellas(Executive Officer)

BoardWalt Doyle(Director)Barkley Stuart(Director)

Board seatPat Kinsel· per SEC Form D · $34.6M raise · filed Dec 2018

Co-investorsAvenir Growth Capital Edmonton Unlimited Winklevoss Capital Avenir Suffolk Equity Partners Tiger Global Management

Epi Biologicsepibiologics.com inApr 2024SEC filingmedium confidence

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSamuel Bjork(Director)Seiji Miyahara(Director)

Board seatAlexandra Cantley· per SEC Form D · $73M raise · filed Apr 2024

Co-investorsAvego BioScience Capital GV (Google Ventures)Mission Biocapital Novartis Venture Fund Roche Venture Fund Samsara BioCapital +3 more

Faraday Pharmaceuticalsfaradaypharma.comOct 2022DefunctSEC filingmedium confidence

Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.

BiotechSeattle, US

Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)

BoardPaulina Hill(Director)Steven Gillis(Executive Officer, Director, Promoter)in

Board seatTerrance McGuire· per SEC Form D · $102.8M raise · filed Nov 2022

Co-investorsARCH Venture Partners OUP (Osage University Partners)

Freenome HoldingsAug 2020SEC filingmedium confidence

Philadelphia, US

Gabriel Otte(Executive Officer, Director)

BoardCharles Roberts(Director)

Board seatAmir Nashat· per SEC Form D · $270M raise · filed Aug 2020

Co-investorsAndreessen Horowitz RA Capital

Glympse Bioglympsebio.comDec 2021SEC filingmedium confidence

BiotechCambridge, US

Gabriel Kwong(Executive Officer)Sirshendu Roopom Banerjee(Executive Officer)

BoardTheresia Guow(Director)Stan Lapidus(Director)

Board seatAmy Schulman· per SEC Form D · $18M raise · filed Dec 2021

Co-investorsGreatPoint Ventures Acrew Capital Aspect Ventures Catalio Capital Management Dns Capital New Leaf Venture Partners +2 more

Icelandic ProvisionsJan 2017SEC filinghigh confidence

New York, US

Mark Alexander(Executive Officer, Director)Anthony Sciortino(Executive Officer)John Heath(Executive Officer)Brant Wutzl(Executive Officer)Gregg Rubin(Executive Officer, Director)

BoardHallbjorn Karlsson(Director)

Board seatTerrance McGuire· per SEC Form D · $9.1M raise · filed Jan 2017

Iora Health in 𝕏Jan 2015acquired by One MedicalSEC filingmedium confidence

Iora Health was a primary care company focused on value-based care for Medicare-eligible seniors, operating clinics with a team-based model including health coaches.

Digital HealthHealthtechWellness & FitnessSan Francisco, US

RUSHIKA FERNANDOPULLE(Executive Officer, Director)CHRISTOPHER J. MCKOWN(Executive Officer, Director)DAVID FIELDING(Executive Officer)ALEXANDER PACKARD(Executive Officer)DAVID JUDGE(Executive Officer)

BoardSTEPHEN KNIGHT(Director)in

Board seatTerry McGuire· per SEC Form D · $48.2M raise · filed Sep 2015

Co-investors.406 Ventures Dag Ventures F-Prime Capital Flare Capital Partners GV (Google Ventures)Lifeforce Capital +5 more

Ironwood Pharmaceuticalsironwoodpharma.com in 𝕏Sep 2016SEC filingmedium confidence

Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.

BiotechDigital HealthHealthtechCambridge, US

PETER M. HECHT(Executive Officer, Director)MARK G. CURRIE(Executive Officer)HALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)

Board seatTerrance G. Mcguire· per SEC Form D · $150M raise · filed Oct 2016

Co-investorsF-Prime Capital Mountain Group Capital Ridgeback Capital Venrock Maverick Ventures

Jnana Therapeutics Inc.Aug 2021SEC filingmedium confidence

Boston, US

Board seatTerrance G. McGuire· per SEC Form D · $50M raise · filed Aug 2021

Co-investorsVersant Ventures

Kallyopekallyope.com inSep 2015SEC filingmedium confidence

Kallyope is a drug discovery and development company working on therapeutic agents for neurological and metabolic diseases.

BiotechDeep TechHealthtechMedical DevicesNew York City, US

Tom Maniatis(Director)Nancy Thornberry(Executive Officer, Director)Kenneth Clark(Executive Officer)

BoardJoshua Wolfe(Director)inTim Kutzkey(Director)

Board seatTerry McGuire· per SEC Form D · $44M raise · filed Oct 2016

Co-investorsDns Capital Illumina Ventures Lux Capital The Column Group

LyndraDec 2023SEC filingmedium confidence

BiotechWatertown, US

Carlo Giovanni Traverso(Director)Amy W. Schulman(Executive Officer, Director)inRobert S. Langer(Director)

BoardZafi Avnur(Director)Edmund Harrigan(Director)Catherine Reynolds(Director)

Board seatAmy Schulman· per SEC Form D · $206.1M raise · filed Dec 2023

Co-investorsBill & Melinda Gates Foundation Kendall Capital Partners

Metacrinemetacrine.comJan 2015SEC filingmedium confidence

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKristina Burow(Director)inRichard Heyman(Director)in

Board seatAmir Nashat· per SEC Form D · $37.8M raise · filed Nov 2016

Co-investorsage1 EcoR1 Capital LAV Lilly Asia Ventures New Enterprise Associates (NEA)Vivo Capital +2 more

Microchips BiotechJun 2015SEC filingmedium confidence

HealthtechLexington, US

Robert S. Langer(Director)Michael J. Cima(Director)David Neafus(Executive Officer)Cheryl R. Blanchard(Executive Officer, Director)Robert Farra(Executive Officer)

Board seatTerrance G. McGuire· per SEC Form D · $18.6M raise · filed Jun 2015

Co-investorsKendall Capital Partners

Morphic Holding, Inc.Mar 2023SEC filingmedium confidence

BiotechWaltham, US

Timothy Springer(Director)Praveen Tiprirneni(Executive Officer, Director)Robert Farrell(Executive Officer)

BoardBarbara Dalton(Director)Ramy Farid(Director)Kevin Bitterman(Director)in

Board seatAmir Nashat· per SEC Form D · $100M raise · filed Mar 2023

Co-investorsAtlas Venture Omega Funds

Navitor Pharmaceuticalsnavitorpharma.comDec 2015SEC filingmedium confidence

BiotechCambridge, US

Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)George Vlasuk(Executive Officer, Director)

BoardJean-Francois Formela(Director)inMarian Nakada(Director)

Board seatAlan Crane· per SEC Form D · $25M raise · filed Mar 2018

Co-investorsage1 Brace Pharma Sanofi Ventures Atlas Venture SR One Capital Management

Noetiknoetik.ai in 𝕏Aug 2024SEC filingmedium confidence

Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets.

AI & Machine LearningBiotechHealthtechSouth San Francisco, US

Jacob Rinaldi(Executive Officer, Director, Promoter)Ronald Alfa(Executive Officer, Director, Promoter)Ron Alfa, MD, PhD(Founder)in

BoardJames Hardiman(Director)in

Board seatAmy Schulman· per SEC Form D · $40M raise · filed Aug 2024

Co-investors11.2 Capital Breakout Ventures Linearis Ventures North South Ventures DCVC (Data Collective)

Nomad Healthnomadhealth.com inDec 2025

Nomad Health operates a self-service digital marketplace connecting clinicians—including doctors, nurses, and allied health professionals—with healthcare facilities for staffing and travel assignments without traditional recruiters.

B2B MarketplacesDigital HealthHealthtechHR TechMarketplacesNew York, US

Alexander Nazem(Director)inMaxwell Laurans(Director)Alexi Nazem(Co-Founder & Board Member)Justin Lambert(CEO)William Eager(Vice President of Engineering)Alexander Pease(Vice President of Product)

Board seatBrian Chee· per SEC Form D

Co-investorsAlleyCorp Icon Ventures .406 Ventures Adams Street Partners First Round Capital HealthQuest Capital +1 more

Pandion TherapeuticsJan 2018SEC filingmedium confidence

BiotechCambridge, US

Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)Anthony Coyle(Executive Officer, Director)Christopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Board seatAlan Crane· per SEC Form D · $80M raise · filed Apr 2020

Co-investorsAccess Biotechnology Versant Ventures

Podimetricspodimetrics.com inApr 2022SEC filingmedium confidence

Podimetrics offers a virtual care service that combines remote foot monitoring with personalized support to help people with complex diabetes prevent foot complications such as amputations.

Digital HealthHealthtechMedical DevicesSomerville, US

David Linders(Executive Officer, Director)Jonathan Bloom(Executive Officer, Director)

BoardAaron Sandoski(Director)in

Board seatAlexandra Cantley· per SEC Form D · $60M raise · filed Apr 2022

Co-investorsNorwich Ventures Scientific Health Development SV Health Investors Rock Health

Primmune Therapeuticsprimmunerx.com in 𝕏Nov 2020SEC filingmedium confidence

Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.

BiotechHealthtechCarlsbad, US

Board seatAmir Nashat· per SEC Form D · $24M raise · filed Nov 2020

Co-investorsBioBrit BioRock Ventures Samsara BioCapital

Pulmatrix OperatingJun 2015SEC filingmedium confidence

BiotechLexington, US

Robert Clarke(Chief Executive Officer and Member of the Board of Directors)David Hava(Chief Scientific Officer)David Edwards(Director)

BoardSteven Gillis(Director)David Maki(Director)

Board seatTerrance McGuire· per SEC Form D · $34.1M raise · filed Jun 2015

Co-investors5AM Ventures

Quralisquralis.com in 𝕏Sep 2025SEC filingmedium confidence

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)Shafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)

Board seatAmy Schulman· per SEC Form D · $24.9M raise · filed Sep 2025

Co-investorsDroia Ventures MC Healthcare Ventures Mission Biocapital Mitsui Global Investment Sanofi Ventures SV Health Investors +2 more

Seismic Therapeuticseismictx.com in 𝕏Sep 2024SEC filingmedium confidence

Seismic Therapeutic is a clinical-stage biotechnology company that uses machine learning to discover and develop immunology therapies for autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesBoston, US

JoTimothy A. Springer(Scientific Advisor / Founder)Kevin(Head of Immunology and Biomarker)Jo Viney, PhD(Founder, President and Chief Executive Officer)Alan Crane(Founder and Chairman of Seismic Therapeutic; Polaris Partners)Tim Springer, PhD(Founder of Seismic Therapeutic; Harvard Medical School and Boston Children's Hospital)

Board seatAlan Crane· per SEC Form D · $146.3M raise · filed Sep 2024

Co-investorsBessemer Venture Partners GV (Google Ventures)Mana Ventures

SequelaeNov 2025SEC filingmedium confidence

Minneapolis, US

Sara Taylor(Executive Officer)Mike Christy(Executive Officer)Gregory Johnson(Executive Officer)Ken Ehlert(Executive Officer, Director)Mark Briesacher(Executive Officer)Mark Pollmann(Executive Officer)

Board seatAmy Schulman· per SEC Form D · $1.5M raise · filed Nov 2025

Seventh Sense BiosystemsJul 2014SEC filingmedium confidence

BiotechCambridge, US

HOWARD BERNSTEIN(Executive Officer)HOWARD WEISMAN(Executive Officer, Director)

BoardROBERT LANGER(Director)ANUPENDRA SHARMA(Director)HARRY WILCOX(Director)

Board seatAlan Crane· per SEC Form D · $10M raise · filed Sep 2017

Sofregensofregen.comSep 2016SEC filingmedium confidence

Sofregen develops medical biomaterials based on purified silk protein for soft tissue regeneration, including injectable fillers and applications such as vocal fold medialization.

BiotechHealthtechMedical DevicesCambridge, US

Milan Kofol(Executive Officer)Doug Sheldon(Director)Anh Hoang(Executive Officer)Howard Weisman(Executive Officer, Director)

Board seatAmir Nashat· per SEC Form D · $9.7M raise · filed Sep 2017

Co-investorsAnzu Partners

SunBird Bio, Inc.May 2023SEC filingmedium confidence

Cambridge, US

Board seatAlexandra Cantley· per SEC Form D · $23.2M raise · filed May 2023

Syros Pharmaceuticals, Inc.Dec 2020SEC filingmedium confidence

Cambridge, MA gene-control biopharma that developed tamibarotene for RARA-overexpressing blood cancers; now in wind-down.

Cambridge, US

Board seatAmir Nashat· per SEC Form D · $121.6M raise · filed Dec 2020

Co-investorsARCH Venture Partners Samsara BioCapital

TRex Holdings Inc.Nov 2024SEC filingmedium confidence

BiotechSouth San Francisco, US

M. Johnston Erwin Jr.(Executive Officer, Director)

BoardEric Pham(Director)Travis Coy(Director)Carol Gallagher(Director)Joel Marcus(Director)Michael Ross(Director)

Board seatAlexandra Cantley· per SEC Form D · $85M raise · filed Nov 2024

XTuit PharmaceuticalsNov 2014SEC filingmedium confidence

BiotechWaltham, US

Garry Nicholson(Executive Officer, Director)Edward Freedman(Executive Officer)Rakesh Jain(Director)

BoardRobert Langer(Director)David Mott(Director)

Board seatAlan Crane· per SEC Form D · $22M raise · filed Sep 2016

Co-investorsCTI Life Sciences Fund L.P.

Allstacksallstacks.com in 𝕏

Allstacks is an AI-agent platform that connects data from software development tools (Jira, GitHub, GitLab, Jenkins) to provide engineering teams and leaders with delivery metrics, risk alerts, and recommendations for planning, managing, and optimizing software creation.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareRaleigh, US

Jeremy Freeman(Founder)Hersh A. Tapadia(Executive Officer, Director)Hersh Tapadia(Founder)inDarrell J. Freeman, Jr.(Executive Officer, Director)Scot Sherwood(Director)

BoardAndrew Drylie(Director)in

Co-investorsAtlassian Ventures Companyon Ventures CreativeCo First Rays Venture Partners Gutbrain Ventures Hyperplane Venture Capital +7 more

Baxter Planningbaxterplanning.com inMay 2024

Baxter Planning provides software and services for service supply chain management, serving enterprises managing complex operational logistics and supplier networks.

AI & Machine LearningEnterprise SoftwareLogistics & Supply ChainSaaS

Anton Chilton(Chief Executive Officer)in

Co-investorsGolub Growth Marlin Equity Partners

Boxeverin 𝕏

Sitecore provides a content management and customer experience platform that uses AI to help brands manage content, data, and personalized digital experiences across multiple channels.

AI & Machine LearningEnterprise SoftwareMarketing Tech

Co-investorsFrontline Ventures Tola Capital

Dyno Therapeuticsdynotx.com in 𝕏

Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.

AI & Machine LearningBiotechWatertown, US

Eric Kelsic(CEO & Cofounder)inSam Sinai(Vice President, Head of ML & Cofounder)inAdrian Veres(Chief Scientific Officer & Cofounder)George Church(Scientific Cofounder)Tomas Bjorklund(Scientific Co-founder)Alan Crane(Executive Chairman & Cofounder, Polaris Entrepreneur Partner)

Co-investorsAndreessen Horowitz CRV (Charles River Ventures)GENERAL INCEPTION GV (Google Ventures)Lux Capital Obvious Ventures +2 more

Egnyteegnyte.com in 𝕏

Egnyte provides software for protecting and managing business-critical content across organizations of all sizes.

AI & Machine LearningCloud ComputingCybersecurityEnterprise Software

Vineet Jain(Chief Executive Officer)inAmrit Jassal(Founder)in

Co-investorsGI Partners TA Associates Floodgate Golub Growth W Capital Partners GV (Google Ventures)+1 more

Folxfolxhealth.com in 𝕏

FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.

Digital HealthHealthtechBoston, US

A.G. Breitenstein(Founder)inLena Ballantine(Executive Officer)Liana M Guzman Weis(Executive Officer, Director)

BoardLynne Chou O'Keefe(Director)inMorgan Cheatham(Director)inLee Shapiro(Director)in

Co-investors7wire Ventures Bessemer Venture Partners Corewell Health Ventures Define Ventures Habitat Partners Seae Ventures +2 more

Jibejibe.com in 𝕏May 2014acquired by iCIMS

AI & Machine LearningEnterprise SoftwareHR TechSaaSNew York, US

Nilanjana Bhowmik(Director)Ross Goldstein(Director)Peter Flint(Director)R. Douglas Higgins(Director)Joe Essenfeld(Executive Officer, Director)Jim Baum(Director)

Co-investorsConverge Montage Capital Runway Growth Capital Sapphire Ventures DFJ Gotham Ventures +1 more

KSQ Therapeuticsksqtx.com in 𝕏Sep 2018

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)FRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)

BoardALAN L. CRANE(Director)

Co-investorsAlpha Wave Global ARCH Venture Partners LAV Lilly Asia Ventures Baillie Gifford Flagship Pioneering

Loblob.com in 𝕏Jan 2026

Lob provides software and hardware infrastructure for automating, personalizing, and tracking direct mail campaigns at scale.

Enterprise SoftwareLogistics & Supply ChainMarketing TechSaaSNew York City, US

Eduardo Browne(Executive Officer)Donnell Vanker(Executive Officer)Harry Zhang(Founder)Leore Avidar(Founder)

Co-investorsFloodgate Frontline Ventures Structural Capital Todd and Rahul’s Angel Fund Y Combinator First Round Capital +3 more

Localyticslocalytics.com inacquired by Upland Software

Localytics is an AI implementation firm that builds, integrates, and operates marketing AI systems for enterprise consumer brands.

AI & Machine LearningEnterprise SoftwareMarketing TechSaaSBoston, US

John Dobrowolski(CEO)inDerick Thompson(VP of Operations)inJuan Yrigoyen(Head of Product)inJoey Rahman(Head of Engineering)Carl Jones(CTO)

Co-investorsBantam Group LaunchCapital MI Ventures Sapphire Ventures Techstars Foundation Capital

LogEntrieslogentries.com in 𝕏acquired by Rapid7

AI & Machine LearningCloud ComputingCybersecurityData & InfrastructureEnterprise Software

Co-investorsFrontline Ventures Floodgate

Matter Neurosciencematter.xyz

Matter develops a consumer iOS app that helps users track positive emotions and brain activity to improve subjective well-being.

AI & Machine LearningConsumerHealthtechMental HealthWellness & Fitness

Axel Bouchon(Founder)Ben Goldhirsh(Co-founder)Chris Shiflett(Co-founder)

Co-investorsARCH Venture Partners Collaborative Fund Exor Ventures

Qstreamqstream.com in 𝕏

Qstream is an enterprise microlearning and knowledge reinforcement platform built on neuroscience algorithms, delivering personalized, spaced learning along with analytics on knowledge retention and job performance readiness.

AI & Machine LearningEdTechEnterprise SoftwareHR TechSaaSBurlington, US

Duncan Lennox(Executive Officer, Director, Promoter)Branch Price Kerfoot(Director)

BoardHambleton Lord(Director)inShay Garvey(Director)inGaye Bok(Director)Harold Copperman(Director)

Co-investorsDelta Partners Excel Venture Management Launchpad Venture Group Enterprise Ireland Bantam Group Frontline Ventures

Sea PharmaceuticalsMay 2026 · $70K

Tavo BiotherapeuticsSeries A · Jun 2026 · $17M

TropicSeries C · Mar 2026 · $105M

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 21

IPOs and acquisitions across the tracked portfolio

Adagio TherapeuticsNASDAQ: IVVDAlectorNASDAQ: ALECaTYR PHARMANASDAQ: ATYRCamp4 Therapeutics CorpNASDAQ: CAMPCardlyticsNASDAQ: CDLXCartesian Therapeutics (NASDAQ: RNAC)NASDAQ: RNACCyclerion TherapeuticsNASDAQ: CYCNDare BioscienceNASDAQ: DAREFate TherapeuticsNASDAQ: FATEFractylNASDAQ: GUTSPulmatrixNASDAQ: PULMScholar RockNASDAQ: SRRKScholar Rock Holding Corp, Inc.NASDAQ: SRRKSeer BiosciencesNASDAQ: SEERTectonic TherapeuticNASDAQ: TECXVaccinexOTC: VCNXX4 PharmaceuticalsNASDAQ: XFORIora Healthacq. by One MedicalJibeacq. by iCIMSLocalyticsacq. by Upland SoftwareLogEntriesacq. by Rapid7

Portfolio news

latest coverage across their companies

Dare Bioscience gets 9.99% L1 Capital stake | DARE SEC Filing - Form SCHEDULE 13G

Dare Bioscience · stocktitan.net · Aug 24, 2026

Dimensional Fund Advisors LP Raises Holdings in Ironwood Pharmaceuticals, Inc. $IRWD

Ironwood Pharmaceuticals · marketbeat.com · Aug 11, 2026

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights - BioSpace

Tectonic Therapeutic · biospace.com · Aug 7, 2026

Earnings call transcript: Cardlytics Q2 2026 results show recovery signs By Investing.com

Cardlytics · investing.com · Aug 5, 2026

Cirrus Therapeutics Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader with Singapore Eye Research Institute (SERI) Collaboration and Additional Financing

Cirrus Therapeutics, Inc. · globenewswire.com · Aug 4, 2026

Alector (NASDAQ:ALEC) Shares Up 7.9% – What’s Next? - Daily Political

Alector · dailypolitical.com · Jul 17, 2026

H.C. Wainwright reiterates Buy on Fractyl Health stock at $8 By Investing.com

Fractyl · investing.com · Jul 15, 2026

Leyden Labs Raises $40M in Funding | FirstWord PHARMA

Leyden Labs · firstwordpharma.com · Jun 29, 2026

Fund performance · per public LP disclosures · 3

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Polaris Growth FundLPs: Los Angeles City Employees' Retirement System, Pension Reserves Investment Management Board	2018	—	36.8%	2.86x	0.57x
Polaris Partners VIIILPs: Hawaii Employees' Retirement System, Los Angeles City Employees' Retirement System	2017	—	15.8%	2.08x	1.10x
Polaris Partners VIILPs: Los Angeles City Employees' Retirement System, Hawaii Employees' Retirement System	2014	—	8.5%	1.88x	0.68x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

What stage does Polaris Partners invest at?: Polaris Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
What is Polaris Partners's typical check size?: Polaris Partners typically writes checks of $500K – $5M.
What sectors does Polaris Partners focus on?: Polaris Partners focuses on Biotech, Consumer, Digital Health, Healthtech.
Where is Polaris Partners located?: Polaris Partners is headquartered in Boston, US.

Media · Podcasts & interviews

featuring the team

Tech Investing Mastermind: Terry McGuire- Co-founder of Polaris Partners & Chairman Emeritus of NVCA

Grace Gong · Terry McGuire

Fireside Chat with Robert Langer (KI) and Terry McGuire (Polaris Partners)

KochInstituteMIT · Terry McGuire

Co-investors · 136

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.

Both backed · 10

Pulmatrix Scholar Rock Scholar Rock Holding Corp, Inc.Agbiome Dewpoint Therapeutics Faraday Pharmaceuticals KSQ Therapeutics Matter Neuroscience MetacrineSyros Pharmaceuticals, Inc.

$50K – $250M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 7

Ankyra Therapeutics Dyno Therapeutics Egnyte Epi Biologics Iora Health Leyden Labs Seismic Therapeutic

$250K – $50M

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

Both backed · 3

Camp4 Therapeutics Corp Dyno Therapeutics Freenome Holdings

$500K – $50M

Bessemer Venture Partners

Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.

Both backed · 3

Fractyl Folx Seismic Therapeutic

$5M – $100M

Floodgate

Floodgate is a venture capital fund that backs founders at the earliest stages, positioning itself as their first true believers.

Both backed · 3

Egnyte LobLogEntries

$500K – $5M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 3

Iora Health Ironwood Pharmaceuticals Leyden Labs

$3M – $10M

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 3

Amagma, Inc.Morphic Holding, Inc.Navitor Pharmaceuticals

$500K – $1M

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.

Both backed · 3

Camp4 Therapeutics Corp Pulmatrix Pulmatrix Operating

$100K – $4M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 3

Fate Therapeutics Navitor Pharmaceuticals Quralis

$5M

Mithril Capital Management

Mithril Capital Management is a multi-billion-dollar investment firm launched in 2012 with a 'Building to Last' mission, backing technology teams building durable businesses in industries overdue for change. Its committed funds are anchored by investor Peter Thiel.

Both backed · 3

Adagio Therapeutics Fractyl Ankyra Therapeutics

SV Health Investors

SV Health Investors is a healthcare-focused private equity and venture capital investment platform managing specialized and diversified funds across biotechnology, healthcare growth equity, and medtech.

Both backed · 3

Alector Podimetrics Quralis

$1M – $20M

Mission Biocapital

Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.

Both backed · 3

Alector Epi Biologics Quralis

$500K

▶124 more co-investors

Techstars DCVC (Data Collective)Sapphire Ventures Venrock Locus Ventures .406 Ventures Versant Ventures Vivo Capital Vida Ventures General Catalyst Foundation Capital CRV (Charles River Ventures)Canaan Partners RRE Ventures Obvious Ventures SoftBank Vision Fund Wildcat Venture Partners RA Capital Flare Capital Partners GreatPoint Ventures SR One Capital Management MPM BioImpact Flagship Pioneering Pfizer Venture Investments Digitalis Ventures Aisling Capital Define Ventures Qiming Venture Partners HealthQuest Capital Catalio Capital Management, LP Lightspeed Venture Partners Khosla Ventures Greylock Partners Founder Collective Uncork Capital Insight Partners Benchmark Felicis Ventures FJ Labs Menlo Ventures Coatue Management B Capital Group Norwest Venture Partners Eniac Ventures Goat Capital NextView Ventures Bling Capital Oak HC/FT C2 Investments Freestyle Capital Headline Scale Venture Partners Stellar Capital Meritech Capital Partners Resolute Ventures Stride VC Bonfire Ventures Next47 Maveron Lowercase Capital 01 Advisors Harrison Metal US Venture Partners BAM Ventures Accomplice Village Global 75 & Sunny Unusual Ventures Better Tomorrow Ventures Standard Capital NextGen Venture Partners Saga Ventures 23andMe Left Lane Capital Moxxie Ventures Zetta Venture Partners OrbiMed Javelin Venture Partners Breakthrough Energy Ventures Highland Capital Partners foobar.vc Owl Ventures Hoxton Ventures Scrum Ventures VitalStage Ventures Amasia Highbury Holdings BIOSPRING PARTNERS Samsung Next Artis Ventures Ten Eleven S32 EQT Life Sciences Strata Capital Partners Forbion Johnson & Johnson Innovation – JJDC Pillar VC Ascension Ventures Autotech Ventures Domain Associates Asset Management Ventures Market One Capital Abingworth Firefly Health byFounders Kurma Partners Republic Capital (ex Republic Labs)Advent Life Sciences Vinyl Capital RiverVest Venture Partners Apollo Health Ventures Alta Partners Cofounders Capital +ND Capital aMoon Medical Excellence Capital Pontifax Venture Capital Avoro Capital Advisors Vertex Ventures HC Borealis Ventures Broadview Ventures ACORN BIOVENTURES Altitude Ventures Management, Llc 3TS Capital Partners

Firms observed investing alongside Polaris Partners, from public investor directories. Shared companies are the overlap with Polaris Partners's recorded portfolio.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Bessemer Venture Partners

Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.

$5M – $100M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

General Catalyst

General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.

$30M